Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Growth, Tolerance, and Functional Biomarkers in Healthy Infants Receiving Dietary Supplements

9. September 2026 aktualisiert von: Société des Produits Nestlé (SPN)

Growth, Tolerance, and Functional Biomarkers in Healthy Infants Receiving Dietary Supplements: A Double-blind, Randomized Placebo-controlled Nutritional Study

This is a double-blind, randomized, placebo-controlled nutritional study aimed at investigating growth, tolerance, and functional biomarkers in healthy infants receiving dietary supplements from birth to 2.5 months of age

Studienübersicht

Detaillierte Beschreibung

This is a double-blind, randomized, placebo-controlled nutritional study in healthy term infants of all feeding types. Approximately 327 infants aged 14 to 28 days at enrollment will be recruited and followed up until 2.5 months of age.

The 8-weeks interventional period will be followed by a 4-week follow-up period. The total duration of the study is approximately 3 months.

The primary objective of this clinical study is to demonstrate non-inferior weight gain from enrollment until 8 weeks of intervention in healthy infants randomized into 3 experimental groups of single probiotic, multi-probiotic, and control group.

The secondary objectives will include growth patterns, gastrointestinal tolerance, gastrointestinal related outcomes, fecal microbiome composition, fecal metabolic status, and biomarkers of gut and immune health as well as safety outcomes from enrollment until 4 weeks after last consumption of the investigational product.

Studientyp

Interventionell

Einschreibung (Geschätzt)

327

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Manila
      • Cavite City, Manila, Philippinen
        • Rekrutierung
        • Health Index Multispecialty and Lying-In Clinic
        • Kontakt:
        • Hauptermittler:
          • Edison Alberto
      • Quezon City, Manila, Philippinen
        • Rekrutierung
        • University of the East Ramon Magsaysay Memorial Medical Center, Inc.
        • Kontakt:
        • Hauptermittler:
          • Vinna Marie Quinones

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  1. Written informed consent has been obtained from at least one parent (or legally acceptable representative [LAR])
  2. Parent(s) / LAR(s) must be able to provide evidence of parental authority and identity
  3. Parent(s) / LAR(s) must understand the informed consent form and other study documents
  4. Parent(s) / LAR(s) are willing and able to comply with scheduled visits and the requirements of the study protocol
  5. Parent(s) / LAR(s) can be contacted directly by telephone throughout the study
  6. Parent(s) / LAR(s) must be able to temporarily store stool samples in a household freezer
  7. Infants may be exclusively breastfed, exclusively formula-fed, or mixed fed with both breast milk and infant formula in any proportion. Parent(s) / LAR(s) must intend to maintain the infant's current mode of feeding until the end of the study period:

    1. For exclusively breastfed infants: parents must intend to continue exclusive breastfeeding. As defined by the World Health Organization, exclusive breastfeeding means that the infant receives only breast milk. No other liquids or solids are given (not even water) with the exception of oral rehydration solution, or drops/syrups of vitamins, minerals, or medicines.
    2. For formula-fed infants (either exclusively or mixed-fed): parent(s) / LAR(s) must intend to maintain the infant's current mode of feeding, plus:

      • Parents / LAR(s) must have previously and independently decided to use formula
      • Infant must be consuming and tolerating a standard cow's milk infant formula not containing probiotics at the time of enrollment
  8. Infant must be healthy based on medical history and physical examination
  9. Infant full-term gestational birth (born 37 weeks, 0 days through 41 weeks, 6 days of gestation)
  10. Infant singleton birth
  11. Infant postnatal age ≥ 14 and ≤ 28 days (date of birth = day 0)
  12. Infant birth weight is appropriate for gestational age (≥ 2500 and ≤ 4500 grams)

Exclusion Criteria:

  1. Infants with conditions requiring specific infant feeding regimens other than those specified in the protocol
  2. Infants who have a medical condition or medical history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:

    1. Evidence of major congenital malformations (e.g., cleft palate, extremity malformation)
    2. Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis)
    3. Previous or ongoing antibiotic usage by the infant, except when given for prophylactic reasons (e.g., erythromycin ophthalmic ointment)
    4. Immunocompromised infants and those who have a central venous catheter
    5. History of admission to the Neonatal Intensive Care Unit, except for admission for jaundice phototherapy
    6. Known or suspected allergy to milk (including lactose) or soy
    7. Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgement of the investigator, would make the infant inappropriate for entry into the study
  3. Infants who are currently receiving or who have received any probiotic supplements or infant formula containing probiotics prior to enrollment
  4. Infants who are currently receiving or who have received any of the following medication(s) or supplement(s) which are known or suspected to affect fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes), stool characteristics (e.g., glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose), growth (e.g. insulin or growth hormone), microbiome-related endpoints (e.g., prebiotic supplements), or gastric acid secretion
  5. Infants whose parent(s) / LAR(s) have not reached the legal age of majority (18 years old)
  6. Infants who are currently or who previously participated in another interventional clinical study
  7. Parent(s) / LAR(s) with family or hierarchical relationships with the research team members

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: EG1 Supplement
Probiotic Supplement in powdered form
Probiotic dietary supplement administered once per day
Andere Namen:
  • Nahrungsergänzungsmittel
Experimental: EG2 Supplement
Probiotic Supplement in powdered form
Probiotic dietary supplement administered once per day
Andere Namen:
  • Nahrungsergänzungsmittel
Placebo-Komparator: CG supplement
Placebo Supplement in powdered form
Placebo dietary supplement administered once per day

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Weight gain velocity
Zeitfenster: From baseline (V1) to 2.5 months (V3)
Weight gain velocity (g/day)
From baseline (V1) to 2.5 months (V3)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Growth Measure: Weight
Zeitfenster: At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
Weight in grams and corresponding weight-for-age Z-scores according to World Health Organization (WHO) child growth standards
At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
Growth Measure: Length
Zeitfenster: At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
Length in centimeters and corresponding length-for-age Z-scores according to WHO child growth standards
At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
Growth Measure: Head circumference
Zeitfenster: At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
Head circumference in centimeters and corresponding head circumference-for-age Z-scores according to WHO child growth standards
At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
Gastrointestinal Tolerance and Gastrointestinal Related Symptoms: Infant Gastrointestinal Symptom Questionnaire (IGSQ)
Zeitfenster: At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
The IGSQ is composed of 13 questions, categorized into 5 symptom domains of stooling, vomiting/spitting-up, crying, fussiness, and flatulence. The total score can range from 13-65 with lower scores indicating lower gastrointestinal symptom burden.
At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
Gastrointestinal Tolerance and Gastrointestinal Related Symptoms: Stool Frequency
Zeitfenster: At baseline (V1; 1-day retrospective record) and 1.5 and 2.5 months (V2 and V3; 3-day prospective diary)
Number of stools per day recorded using a gastrointestinal symptom and behavior diary.
At baseline (V1; 1-day retrospective record) and 1.5 and 2.5 months (V2 and V3; 3-day prospective diary)
Gastrointestinal Tolerance and Gastrointestinal Related Symptoms: Stool Consistency
Zeitfenster: At baseline (V1; 1-day retrospective record) and 1.5 and 2.5 months (V2 and V3; 3-day prospective diary)
Stool consistency recorded on a 5-point scale (1=watery, 5=hard) using a gastrointestinal symptom and behavior diary
At baseline (V1; 1-day retrospective record) and 1.5 and 2.5 months (V2 and V3; 3-day prospective diary)
Gastrointestinal Tolerance and Gastrointestinal Related Symptoms: Crying and Sleeping
Zeitfenster: At baseline (V1; 1-day retrospective record) and 1.5 and 2.5 months (V2 and V3; 3-day prospective diary)
Crying and sleeping time per day recorded using a gastrointestinal symptom and behavior diary
At baseline (V1; 1-day retrospective record) and 1.5 and 2.5 months (V2 and V3; 3-day prospective diary)
Gastrointestinal Tolerance and Gastrointestinal Related Symptoms: volume of formula consumed per day/number of breastmilk feeds per day
Zeitfenster: At baseline (V1; 1-day retrospective record) and 1.5 and 2.5 months (V2 and V3; 3-day prospective diary)
Volume of formula consumed per day (mL) and number of breastmilk feeds per day recorded using a gastrointestinal symptom and behavior diary
At baseline (V1; 1-day retrospective record) and 1.5 and 2.5 months (V2 and V3; 3-day prospective diary)
Gastrointestinal Tolerance and Gastrointestinal Related Symptoms: Infant Colic Questionnaire (ColiQ)
Zeitfenster: At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
The ColiQ is a 16-item questionnaire that includes 10 questions describing infant colic symptoms and 6 questions describing parental impact. The total score can range from 0 to 100, with higher scores indicating an overall better state (fewer / less severe symptoms and lower parental impact).
At baseline (V1), 1.5 months (V2), and 2.5 months (V3)
Fecal Microbiome: Abundance of Probiotic Strains
Zeitfenster: At baseline (V1) and 2.5 months (V3)
Fecal probiotic strain abundance
At baseline (V1) and 2.5 months (V3)
Fecal Microbiome: Overall Compositional Profile
Zeitfenster: At baseline (V1) and 2.5 months (V3)
Overall fecal microbiota composition, including diversity and functional characteristics
At baseline (V1) and 2.5 months (V3)
Fecal Metabolic Status: Fecal pH
Zeitfenster: At baseline (V1) and 2.5 months (V3)
Fecal pH
At baseline (V1) and 2.5 months (V3)
Fecal Metabolic Status: Concentrations of Fecal Organic Acids
Zeitfenster: At baseline (V1) and 2.5 months (V3)
Concentration of fecal organic acids
At baseline (V1) and 2.5 months (V3)
Fecal Metabolic Status: Fecal Metabolomic Profile
Zeitfenster: At baseline (V1) and 2.5 months (V3)
Relative and/or absolute concentrations of fecal metabolites
At baseline (V1) and 2.5 months (V3)
Fecal Markers: Fecal Total Secretory Immunoglobulin A (sIgA)
Zeitfenster: At 2.5 months (V3) in exclusively formula-fed infants only
Concentration of fecal sIgA
At 2.5 months (V3) in exclusively formula-fed infants only
Fecal Markers: Fecal Alpha-1 Antitrypsin
Zeitfenster: At baseline (V1) and 2.5 months (V3) for all infants regardless of feeding regimen
Concentration of fecal alpha-1 antitrypsin
At baseline (V1) and 2.5 months (V3) for all infants regardless of feeding regimen
Safety Outcome: Physical Examination
Zeitfenster: At baseline (V1), 1.5 months (V2) and 2.5 months (V3)
Number of participants with abnormal physical examination findings (major body systems)
At baseline (V1), 1.5 months (V2) and 2.5 months (V3)
Safety Outcome: Vital signs
Zeitfenster: At baseline (V1), 1.5 months (V2) and 2.5 months (V3)
Number of participants with abnormal vital signs (temperature, pulse, respiration)
At baseline (V1), 1.5 months (V2) and 2.5 months (V3)
Safety Outcome: Adverse Events
Zeitfenster: From baseline to 3.5 months
Reported adverse events including type, incidence, severity, seriousness, and relation to the intervention
From baseline to 3.5 months
Safety Outcome: Concomitant Medications
Zeitfenster: From baseline to 3.5 months
Reported concomitant medications used to treat illnesses and other conditions, including name, dose, and duration
From baseline to 3.5 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Dr Edison Alberto
  • Hauptermittler: Dr Vinna Marie Quinones, University of East Ramon Magsaysay Memorial Medical center, Philippines

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

11. August 2026

Primärer Abschluss (Geschätzt)

31. Juli 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

10. Februar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. Juni 2026

Zuerst gepostet (Tatsächlich)

5. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

14. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • 2403INF

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren